Daxor Stock Quote DXR - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

9.65

Bid

9.40

Ask

12.90

Volume

503

9.65 Day's Range 9.80

7.11 52 Week Range 13.30

Market Cap

45.654M

Previous Close

9.65

Open

9.80

Last Trade

9.79

Last Trade Time

Financial Volume

$ 4,854

VWAP

9.65

Average Volume (3m)

2,439

Shares Outstanding

4,196,182

Dividend Yield

PE Ratio

162.39

Earnings Per Share (EPS)

0.07

Revenue

163k

Net Profit

281k

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and compos... Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. Show more

Sector

Surgical,med Instr,apparatus

Industry

Misc Health & Allied Svc,nec

Website

www.daxor.com

Headquarters

Oak Ridge, New Jersey, USA

Founded

2010

Daxor Corporation is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DXR. The last closing price for Daxor was $9.65. Over the last year, Daxor shares have traded in a share price range of $ 7.11 to $ 13.30.

Daxor currently has 4,196,182 shares outstanding. The market capitalization of Daxor is $45.65 million. Daxor has a price to earnings ratio (PE ratio) of 162.39.

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE...

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

450-Bed Hospital Purchases BVA-100™ Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American...

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces an investor call to be held on Monday...

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to...

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis...

Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend]

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.05	0.520833333333	9.6	9.9399	9.55	2427	9.7543246	CS
4	0.96	11.0471806674	8.69	9.9399	8.4	2732	9.51001026	CS
12	1.26	15.0178784267	8.39	9.9399	7.19	2439	8.6701194	CS
26	1.24	14.744351962	8.41	10.04	7.11	2730	8.76625123	CS
52	-1.35	-12.2727272727	11	13.3	7.11	3780	9.41651657	CS
156	-1.32	-12.032816773	10.97	14.55	7.11	4094	10.22036622	CS
260	-1.32	-12.032816773	10.97	14.55	7.11	4094	10.22036622	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M